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Evaluation of three commercial real-time PCR
kits for dengue diagnosis
F. Najioullah, M. Angla-Gre, F. Viron, R. Cesaire
Hospital P Zobda-Quitman, Fort de France, France
Background: Dengue is the most important arthropod-borne
viral disease in the world. Since dengue clinical manifestations
are similar to those of many other febrile syndromes, the avail-
ability of dengue-speciﬁc laboratory tests is useful for appropriate
management of patients. Dengue is endemoepidemic inMar-
tinique, a French Caribbean island. The island has experienced
epidemics caused by DENV-2/DENV-4 in2005, DENV-2 in2007,
DENV-1/DENV-4 in2010 and DENV-2/DENV-4 in2013. In our virol-
ogy unit, RT-PCR (Hemi-nested protocol from Lanciotti et al., J Clin
Microbiol 1992) is systematically run for patients consulting at hos-
pital facilities with acute febrile disease and admitted until day 8
of fever onset. This technique is considered as the gold standard
but it is time consuming and at high risk of contamination. More-
over there is a need for standardized dengue RT-PCR with internal
controls.
Methods & Materials: In the present study, we evaluated
the performance of three commercialdengue real-time PCR kits
(SimplexaTM Dengue PCR assay: Focus Diagnostic, RealStar® Dengue
RT-PCR kit 1.0: Altona Diagnostics, Geno-Sen’s Dengue 1-4 Real-time
PCR kit: Genome Diagnostics Pvt) using 162 samples positive with
the hemi-nested RT-PCR (46 DENV-1, 37 DENV-2, 33 DENV-3, and
46 DENV-4). In addition, 70 negative serum specimens were used
to evaluate speciﬁcity. All three kits included an internal control.
RNA extraction was performed using the NucliSens easyMAG®
(BioMérieux).
Results: Geno-Sen’s, RealStar®, and SimplexaTM tests were
positive in 138 (85.1%), 135 (83.3%), and 151 (93.2%) samples,
respectively. The sensitivity of SimplexaTM was signiﬁcantly higher
than Geno-Sen’s (Chi 2, p =0.009) and RealStar® (p =0.005). Com-
pared to the in-place reference RT-PCR, the speciﬁcity was 100%
for Geno-Sen’s and SimplexaTM and 98% for Real Star.According
to dengue genotypes, the sensitivity was for DENV-1 (91%, 78%
and 96%), for DENV-2 (89%, 87%, and 92%) for DENV-3 (91%, 91%,
91%), for DENV-4 (72%, 80% and 94%) by Geno-Sen’s, Real Star®
and SimplexaTM kits respectively. Simplexa is the only kit providing
genotyping of virus.
Conclusion: The good performance of the SimplexaTM Dengue
PCR assay at the detection and genotyping level in combination
with an automated extraction is suitable for diagnosis during
dengue outbreaks in tropical areas.
http://dx.doi.org/10.1016/j.ijid.2014.03.1189
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Diagnosis of extrapulmonary TB: Experience
with the Xpert MTB/Rif assay
C.N. Govind ∗, K. Moodley, A.K. Peer
Lancet Labs, Kwazulu Natal, South Africa
Background: South Africa has the 3rd highest number of TB
cases in the world and the 5th highest number of drug-resistant
cases (WHO, 2011). In 2009, 16% of newly diagnosed cases were
extrapulmonary and 9070 cases were conﬁrmed MDR-TB. Current
diagnostic methods lack sensitivity and results are only available
weeks later. TheXpertMTB/RIF assayprovidesa rapiddiagnosis and
a rifampicin susceptibility result. AlthoughXpertMTB/RIF assayhas
a high sensitivity for smear negative sputum samples, it has not
been validated as yet for the diagnosis of extrapulmonary TB.
In this study, we describe our experience with the Xpert assay
on extrapulmonary specimens.
Methods & Materials: All extrapulmonary specimens received
at Lancet Laboratories in KZN, for TB diagnostics from November
2011 through to July 2012 were retrospectively evaluated. Xpert
MTB/Rif assay and TB culture were performed on all specimens.
Positive cultures were conﬁrmed as Mycobacterium tuberculosis
complex and subjected to drug susceptibility testing using theMGIT
system. Data was extracted from the Meditech system.
Results: A total of 3069 extrapulmonary specimens were
processed using the Xpert system. Clinical specimens included
CSF’s (936), pleural ﬂuid (368), lymph nodes (283), urine (219),
tissue (204), peritoneal ﬂuid (63), liver (57) and pus (53). 1092
were excluded as TB culture was not performed. Of the remaining
1977 specimens, 252(12.7%) were TB culture positive. Of these,
180(71.4%) tested TB PCR positive and 72(28.6%) tested negative.
Of the 1725 TB culture negative samples, 103(5.9%) tested TB PCR
positive. Sensitivity of the PCR on extrapulmonary specimens in
this study was 71.6% and the speciﬁcity was 94%. PPV and NPV
were 64.5% and 95.7% respectively.
Conclusion: The sensitivity of the XpertMTB/Rif assay on extra-
pulmonary specimens in this study, is similar to that of the gene
xpert on a single smear negative sputum specimen. This sensi-
tivity coupled with the rapid turn-around-time, makes the Xpert
MTB/RIF assay a suitable addition to the initial testing algorithm in
the diagnosis of extra-pulmonary TB.
http://dx.doi.org/10.1016/j.ijid.2014.03.1190
